Impact of Hereditary Hemorrhagic Teleangiectasia on Quality of Life

Holderried, Martin; Baur, Manuela; Pfister, Markus

doi:10.2174/1874428101004010055

Cited by 3 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although telangiectasias can lead to a life‐threatening hemorrhage in the brain, lung, and liver, HHT most commonly manifests in the head and neck as recurrent epistaxis . Due to its unpredictable and often severe nature, HHT‐related epistaxis can be a significant detriment to patients’ quality‐of‐life (QOL) .…”

Section: Introductionmentioning

confidence: 99%

Laser‐Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

Background and Objectives Hereditary hemorrhagic telangiectasia (HHT), also known as Osler–Weber–Rendu disease, causes recurrent mucous membrane hemorrhage, especially epistaxis. In this systematic review, we discuss the efficacies of the three most common laser photocoagulation treatments for HHT‐related epistaxis. Study Design/Materials and Methods A systematic literature search was conducted in PubMed and MEDLINE from database inception to March 2019. Studies reporting epistaxis outcomes following argon, neodymium‐doped yttrium aluminum garnet (Nd:YAG), and diode laser photocoagulation for HHT were included. χ2 and Barnard's exact tests were utilized to detect differences in reduced epistaxis frequency and intensity rates. Results Fifteen out of 157 published studies met our eligibility criteria, spanning a collective 362 patients. Argon, Nd:YAG, and diode laser therapy reduced epistaxis frequency in 90.4%, 88.9%, and 71.1% of patients, respectively, and reduced epistaxis intensity in 87.8%, 87.2%, and 71.1% of patients, respectively. Diode laser photocoagulation significantly underperformed in both outcome measurements when compared with argon (frequency: P = 0.005; intensity: P = 0.034) and Nd:YAG (frequency: P = 0.012; intensity: P = 0.041). There was no significant difference between argon and Nd:YAG in reducing HHT epistaxis frequency (P = 0.434) or intensity (P = 0.969). Categorizing HHT patients by clinical severity demonstrated a higher rate of improvement in the mild‐moderate group compared with the severe group in both argon (P < 0.001) and Nd:YAG (P < 0.001) therapeutic methods. While no significant differences were found in rates of improved epistaxis outcomes between argon and Nd:YAG in mild‐moderate HHT patients (frequency: P = 0.061; intensity: P = 0.061), Nd:YAG demonstrated greater rates of reduction in epistaxis frequency (P = 0.040) and intensity (P = 0.028) than argon among severe HHT patients. Conclusions HHT is a lifelong disease, plaguing patients with debilitating epistaxis. Intranasal laser photocoagulation of telangiectasias using argon or Nd:YAG laser therapy can yield improved epistaxis outcomes compared with diode laser photocoagulation. In severe cases of HHT, Nd:YAG laser therapy provides greater improvements in epistaxis outcomes than argon photocoagulation. Lasers Surg. Med. © 2019 Wiley Periodicals, Inc.

show abstract

Section: Introductionmentioning

confidence: 99%

Laser‐Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Christoph Löffler et al give a nice overview on QOL in Cochlear Implant patients which has increasingly been investigated over the past years [7]. Another paper by Holderried et al updates information on QOL in patients with hereditary hemorrhagic teleangiectasia (HHT) [8]. Furthermore, Sertel et al give an overview on QOL measurements in patients treated with Traditional Chinese Medicine (TCM) [9].…”

mentioning

confidence: 99%